Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes only
HR 0.64 [0.53, 0.76]
2 studies · 1443 participants
Moderate

Intervention not reported

Overall survival (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation

The intervention showed no clear difference in overall survival (at 36 months) (moderate certainty).

1 finding from 1 review

Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
HR 0.93 [0.77, 1.13]
9 studies · 1249 participants
Moderate

Intervention not reported

Overall survival at six and 12 months · adults with newly diagnosed warm AIHA

The review found no eligible studies for this question.

1 finding from 1 review

Disease‐modifying treatments for primary autoimmune haemolytic anaemia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found